
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
By continuing to use our site, you agree to our Private Policy and Terms of Use.
HIVers who are on a therapy regimen containing a nonnucleoside reverse transcriptase inhibitor instead of a protease inhibitor are less likely to report sexual side effects, according to a study in the December 15 edition of Journal of Acquired Immune Deficiency Syndromes. Earlier studies have shown that up to 70% of HAART recipients report sexual problems, with protease inhibitors being commonly linked with sexual side effects. Study subjects were asked to rate their satisfaction with their sex lives on a scale from a low of 1 to a high of 100. Patients on NNRTI regimens or who switched from protease inhibitors to NNRTI drugs were the most likely to rate high levels of sexual satisfaction. 'The fact that NNRTIs have been associated with an improvement in sexual satisfaction may be an additional reason to offer an NNRTI-containing regimen as a first-line scheme of HAART,' the researchers concluded. They also recommended additional studies to see if such results led to better adherence to medication.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Don’t miss our latest news! Sign up today for our free newsletter.
Plus: Featured Video
Latest Stories
‘Kokomo City’ Gives a Searing Look Into Lives of Black Trans Sex Workers
August 18 2023 12:40 PM